Drug Trial Radar · NCT06029270
Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
156
Planned (sponsor's estimate)
Start
Jul 15, 2024
Primary completion
Apr 30, 2029
Study completion Apr 30, 2029
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Sep 8, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial tests the addition of BMS-986016 (relatlimab) to the usual immunotherapy after initial treatment for nasopharyngeal cancer that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. The usual approach of treatment is initial treatment with chemotherapy such as the combination of cisplatin (or carboplatin) and gemcitabine, along with immunotherapy such as nivolumab. After the initial treatment is finished, patients may continue to receive additional immunotherapy. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Gemcitabine is a chemotherapy drug that blocks the cells from making deoxyribonucleic acid (DNA) and may kill cancer cells. Giving BMS-986016 in addition to the usual immunotherapy after initial treatment may extend the time without the tumor cells growing or spreading longer than the usual approach in patients with recurrent or metastatic nasopharyngeal cancer.
Conditions
- Metastatic Nasopharyngeal Carcinoma
- Recurrent Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma AJCC v8
Interventions
Biospecimen CollectionProcedure
Undergo blood sample collection
Bone ScanProcedure
Undergo bone scan
CarboplatinDrug
Given IV
CisplatinDrug
Given IV
Computed TomographyProcedure
Undergo CT or PET/CT
GemcitabineDrug
Given IV
Magnetic Resonance ImagingProcedure
Undergo MRI
NivolumabBiological
Given IV
Positron Emission TomographyProcedure
Undergo PET/CT
RelatlimabBiological
Given IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free survival (PFS)Time frame: Time from randomization to progressive disease (PD) or death due to any cause, assessed up to 6 years
Locations
96 sites in 5 countries. Site status is shown where the registry gives one.
Kaiser Permanente Dublin
Dublin, California · Recruiting
Kaiser Permanente-Fremont
Fremont, California · Recruiting
Kaiser Permanente Fresno Orchard Plaza
Fresno, California · Recruiting
Kaiser Permanente-Fresno
Fresno, California · Recruiting
Keck Medicine of USC Koreatown
Los Angeles, California · Recruiting
Los Angeles General Medical Center
Los Angeles, California · Recruiting
USC / Norris Comprehensive Cancer Center
Los Angeles, California · Recruiting
Kaiser Permanente- Modesto MOB II
Modesto, California · Recruiting
Kaiser Permanente-Modesto
Modesto, California · Recruiting
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California · Recruiting
Kaiser Permanente-Oakland
Oakland, California · Recruiting
Stanford Cancer Institute Palo Alto
Palo Alto, California · Recruiting
Kaiser Permanente-Roseville
Roseville, California · Recruiting
Kaiser Permanente Downtown Commons
Sacramento, California · Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California · Recruiting
Kaiser Permanente-South Sacramento
Sacramento, California · Recruiting
Kaiser Permanente-San Francisco
San Francisco, California · Recruiting
Kaiser Permanente-Santa Teresa-San Jose
San Jose, California · Recruiting
Kaiser Permanente San Leandro
San Leandro, California · Recruiting
Kaiser San Rafael-Gallinas
San Rafael, California · Recruiting
Kaiser Permanente Medical Center - Santa Clara
Santa Clara, California · Recruiting
Kaiser Permanente-Santa Rosa
Santa Rosa, California · Recruiting
Kaiser Permanente-South San Francisco
South San Francisco, California · Recruiting
Kaiser Permanente-Vallejo
Vallejo, California · Recruiting
Kaiser Permanente-Walnut Creek
Walnut Creek, California · Recruiting
Emory University Hospital Midtown
Atlanta, Georgia · Recruiting
Kaiser Permanente Moanalua Medical Center
Honolulu, Hawaii · Recruiting
Saint Alphonsus Cancer Care Center-Boise
Boise, Idaho · Suspended
Saint Alphonsus Cancer Care Center-Caldwell
Caldwell, Idaho · Suspended
Kootenai Health - Coeur d'Alene
Coeur d'Alene, Idaho · Recruiting
Saint Alphonsus Cancer Care Center-Nampa
Nampa, Idaho · Suspended
Kootenai Clinic Cancer Services - Post Falls
Post Falls, Idaho · Recruiting
Kootenai Clinic Cancer Services - Sandpoint
Sandpoint, Idaho · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
University of Illinois
Chicago, Illinois · Active not recruiting
Carle at The Riverfront
Danville, Illinois · Recruiting
Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois · Recruiting
Carle Physician Group-Effingham
Effingham, Illinois · Recruiting
Northwestern Medicine Cancer Center Delnor
Geneva, Illinois · Recruiting
Northwestern Medicine Glenview Outpatient Center
Glenview, Illinois · Recruiting
Showing 40 of 96 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.